GOSS
Price
$0.84
Change
-$0.02 (-2.33%)
Updated
Dec 24 closing price
86 days until earnings call
MRUS
Price
$42.41
Change
-$0.04 (-0.09%)
Updated
Dec 24 closing price
69 days until earnings call
Ad is loading...

GOSS vs MRUS

Header iconGOSS vs MRUS Comparison
Open Charts GOSS vs MRUSBanner chart's image
Gossamer Bio
Price$0.84
Change-$0.02 (-2.33%)
Volume$487.32K
CapitalizationN/A
Merus
Price$42.41
Change-$0.04 (-0.09%)
Volume$292.19K
CapitalizationN/A
GOSS vs MRUS Comparison Chart
Loading...
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GOSS vs. MRUS commentary
Dec 25, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GOSS is a Hold and MRUS is a Hold.

Ad is loading...
COMPARISON
Comparison
Dec 25, 2024
Stock price -- (GOSS: $0.84 vs. MRUS: $42.41)
Brand notoriety: GOSS and MRUS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GOSS: 33% vs. MRUS: 52%
Market capitalization -- GOSS: $191.23M vs. MRUS: $2.9B
GOSS [@Biotechnology] is valued at $191.23M. MRUS’s [@Biotechnology] market capitalization is $2.9B. The market cap for tickers in the [@Biotechnology] industry ranges from $385.62B to $0. The average market capitalization across the [@Biotechnology] industry is $2.4B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GOSS’s FA Score shows that 0 FA rating(s) are green whileMRUS’s FA Score has 1 green FA rating(s).

  • GOSS’s FA Score: 0 green, 5 red.
  • MRUS’s FA Score: 1 green, 4 red.
According to our system of comparison, GOSS is a better buy in the long-term than MRUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GOSS’s TA Score shows that 6 TA indicator(s) are bullish while MRUS’s TA Score has 4 bullish TA indicator(s).

  • GOSS’s TA Score: 6 bullish, 3 bearish.
  • MRUS’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, GOSS is a better buy in the short-term than MRUS.

Price Growth

GOSS (@Biotechnology) experienced а -3.28% price change this week, while MRUS (@Biotechnology) price change was -5.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.85%. For the same industry, the average monthly price growth was -1.81%, and the average quarterly price growth was +3.32%.

Reported Earning Dates

GOSS is expected to report earnings on Mar 21, 2025.

MRUS is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (-0.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRUS($2.9B) has a higher market cap than GOSS($191M). MRUS YTD gains are higher at: 54.218 vs. GOSS (-7.518). GOSS has higher annual earnings (EBITDA): -52.24M vs. MRUS (-228.46M). MRUS has more cash in the bank: 632M vs. GOSS (327M). MRUS has less debt than GOSS: MRUS (11M) vs GOSS (204M). GOSS has higher revenues than MRUS: GOSS (105M) vs MRUS (35.9M).
GOSSMRUSGOSS / MRUS
Capitalization191M2.9B7%
EBITDA-52.24M-228.46M23%
Gain YTD-7.51854.218-14%
P/E RatioN/AN/A-
Revenue105M35.9M292%
Total Cash327M632M52%
Total Debt204M11M1,855%
FUNDAMENTALS RATINGS
GOSS vs MRUS: Fundamental Ratings
GOSS
MRUS
OUTLOOK RATING
1..100
2763
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
56
Fair valued
PROFIT vs RISK RATING
1..100
10023
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
4857
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GOSS's Valuation (43) in the Pharmaceuticals Major industry is in the same range as MRUS (56) in the Biotechnology industry. This means that GOSS’s stock grew similarly to MRUS’s over the last 12 months.

MRUS's Profit vs Risk Rating (23) in the Biotechnology industry is significantly better than the same rating for GOSS (100) in the Pharmaceuticals Major industry. This means that MRUS’s stock grew significantly faster than GOSS’s over the last 12 months.

MRUS's SMR Rating (97) in the Biotechnology industry is in the same range as GOSS (98) in the Pharmaceuticals Major industry. This means that MRUS’s stock grew similarly to GOSS’s over the last 12 months.

GOSS's Price Growth Rating (48) in the Pharmaceuticals Major industry is in the same range as MRUS (57) in the Biotechnology industry. This means that GOSS’s stock grew similarly to MRUS’s over the last 12 months.

GOSS's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as MRUS (100) in the Biotechnology industry. This means that GOSS’s stock grew similarly to MRUS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GOSSMRUS
RSI
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 13 days ago
81%
N/A
Declines
ODDS (%)
N/A
Bearish Trend 6 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
73%
View a ticker or compare two or three
Ad is loading...
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JSJAX16.690.17
+1.03%
JHancock Small Cap Dynamic Growth A
FSTRX31.240.22
+0.71%
Federated Hermes MDT Large Cap Value A
FRIFX11.920.02
+0.17%
Fidelity Real Estate Income
MSBPX8.10N/A
N/A
Morgan Stanley Global Focus Rl Est R6
AFCGX17.13-0.01
-0.06%
American Century Focused Intl Gr G

GOSS and

Correlation & Price change

A.I.dvisor indicates that over the last year, GOSS has been loosely correlated with MEIP. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GOSS jumps, then MEIP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GOSS
1D Price
Change %
GOSS100%
-1.64%
MEIP - GOSS
46%
Loosely correlated
N/A
CGEM - GOSS
45%
Loosely correlated
+3.37%
SYRE - GOSS
41%
Loosely correlated
-1.06%
APVO - GOSS
41%
Loosely correlated
+2.76%
VIR - GOSS
41%
Loosely correlated
+0.54%
More

MRUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRUS has been loosely correlated with CYTK. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if MRUS jumps, then CYTK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRUS
1D Price
Change %
MRUS100%
-0.09%
CYTK - MRUS
35%
Loosely correlated
-0.86%
IMTX - MRUS
35%
Loosely correlated
+0.42%
VCYT - MRUS
34%
Loosely correlated
+0.46%
XENE - MRUS
33%
Poorly correlated
+0.73%
GOSS - MRUS
33%
Poorly correlated
-1.64%
More